Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial

This pre-specified cognitive substudy of the SPRINT trial — which randomized 9,361 hypertensive adults to intensive (SBP target <120 mmHg) versus standard (SBP target <140 mmHg) blood pressure treatment — evaluated dementia and mild cognitive impairment (MCI) as primary outcomes after a mean follow-up of 3.3 years.

Intensive BP control significantly reduced probable MCI (14.6 vs 18.3 per 1,000 person-years; HR 0.81, 95% CI 0.69–0.95). The primary outcome of probable dementia alone was not statistically significantly reduced (HR 0.83, 95% CI 0.67–1.04), likely because the study was underpowered for this endpoint after the main SPRINT trial was stopped early for cardiovascular benefit. A composite of probable dementia or MCI was significantly reduced.

The mechanistic link between hypertension and dementia operates through multiple pathways that overlap substantially with coronary artery disease: arterial stiffness, small vessel disease, cerebral hypoperfusion, and progression of white matter lesions. Effective blood pressure reduction reduces subclinical cerebrovascular disease — measurable by white matter hypervolume MRI — as well as coronary atherosclerosis progression.

The SPRINT MIND findings extend the clinical argument for intensive BP control beyond cardiovascular event prevention to cognitive preservation. This has particular relevance for patients who might otherwise accept borderline hypertension: the risk accumulates across multiple end-organ systems simultaneously.

We rate the evidence strong. A pre-specified substudy of a landmark RCT demonstrating that intensive blood pressure control reduces mild cognitive impairment — extending the rationale for aggressive hypertension management beyond cardiovascular endpoints to brain health preservation.